Capivasertib

• Capivasertib is an AKT inhibitor, a type of targeted cancer therapy.
• Its primary mechanism involves blocking the AKT pathway, crucial for cancer cell proliferation and survival.
• It is approved for treating certain advanced breast cancers, often in combination with endocrine therapy.
• Common side effects include diarrhea, skin rash, and hyperglycemia.
• Patients should discuss all drug information and potential side effects with their healthcare provider.

What is Capivasertib and How Does It Work?

Capivasertib is an oral, potent, and selective inhibitor of all three AKT isoforms (AKT1, AKT2, and AKT3). It is a crucial component of targeted cancer therapy, specifically designed to disrupt the signaling pathways that drive tumor growth. AKT, also known as protein kinase B, is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes, including metabolism, proliferation, cell survival, growth, and angiogenesis. Dysregulation of the AKT pathway is frequently observed in various human cancers, leading to uncontrolled cell growth and resistance to conventional treatments. This makes AKT a significant therapeutic target in oncology.

The capivasertib mechanism of action involves binding to the ATP-binding site of AKT, thereby preventing its activation and subsequent phosphorylation of downstream targets. By inhibiting AKT, Capivasertib effectively suppresses the signaling cascade that promotes cell division, inhibits apoptosis (programmed cell death), and enhances tumor survival. This targeted approach makes Capivasertib particularly effective in cancers where the AKT pathway is hyperactive due to mutations or other molecular alterations, offering a more precise way to combat tumor progression. For instance, in hormone receptor-positive, HER2-negative advanced breast cancer, the PI3K/AKT/PTEN pathway is often dysregulated, making it a viable target for Capivasertib, thereby improving treatment efficacy.

Capivasertib: Clinical Uses, Dosage, and Side Effects

Capivasertib has demonstrated significant clinical utility, particularly in the treatment of certain advanced cancers. Its primary approved use is in combination with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have experienced disease progression or recurrence following at least one endocrine-based regimen. This combination therapy targets both the hormone receptor pathway and the AKT pathway, offering a dual approach to overcome resistance mechanisms and improve patient outcomes. The typical dosage involves oral administration, usually twice daily for a specified period, as determined by the treating oncologist based on individual patient factors and treatment response, highlighting the personalized nature of cancer treatment.

Understanding capivasertib drug information is vital for both patients and healthcare providers. It is crucial to adhere to prescribed dosages and schedules to maximize efficacy and manage potential adverse effects. As with any potent oncology medication, Capivasertib comes with a profile of potential side effects. Patients should be thoroughly informed about capivasertib uses and side effects before initiating treatment. Common side effects often include:

• Diarrhea: Often manageable with anti-diarrheal medications.
• Skin rash: Can range from mild to severe, sometimes requiring topical treatments or dose adjustments.
• Hyperglycemia (high blood sugar): Regular monitoring of blood glucose levels is necessary, especially for patients with pre-existing diabetes.
• Nausea and vomiting: Can be managed with antiemetic drugs.
• Fatigue: A common side effect across many cancer therapies.
• Stomatitis (mouth sores): Oral hygiene and specific rinses may help.

Less common but serious side effects can also occur, such as interstitial lung disease and venous thromboembolism. Patients are advised to report any new or worsening symptoms to their healthcare team promptly. Regular monitoring through blood tests and clinical evaluations is essential to detect and manage adverse reactions effectively, ensuring the best possible therapeutic outcomes while maintaining patient safety and quality of life. Always consult a qualified healthcare professional for personalized medical advice and treatment plans.